NIH PAR · NINDS · R61, R33
PAR-25-225: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.
- NOFO number
- PAR-25-225
- Type
- PAR
- Activity code
- R61R33
- Primary institute
- NINDS · National Institute of Neurological Disorders and Stroke
- Clinical trials
- Not Allowed
- Posted
- Nov 4, 2024
- Opens
- Jan 19, 2025
- Expires
- Oct 21, 2027
PAR-25-225 due dates
4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 18, 2025 | February 18, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 18, 2025 | June 18, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 20, 2025 | October 20, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 18, 2026 | February 18, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 18, 2026 | June 18, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 20, 2026 | October 20, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 18, 2027 | February 18, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 18, 2027 | June 18, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 20, 2027 | October 20, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-225
NIH RePORTER lists 8 projects funded under PAR-25-225 in FY2022–FY2026, with $3.4M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
8
Distinct projects, FY2022–FY2026
New awards
8
Type 1 (new project) award records
NIH funding
$3.4M
Award dollars under PAR-25-225, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 8 | 8 | $3.4M |
Institutions with the most funding
- University of Florida$766K · 2 projects
- Johns Hopkins University$581K · 1 project
- Mayo Clinic Rochester$501K · 1 project
- University of Minnesota$487K · 1 project
- Research Inst Nationwide Children's Hosp$381K · 1 project
- University of Michigan at Ann Arbor$378K · 1 project
- Loyola University Chicago$342K · 1 project
Funding institutes
- NINDS$3.4M · 8
Activity codes funded
- R618 records
Most recent new awards
- CRISPR/Cas9-Mediated Therapeutic Targeting of CAG Repeats in Spinocerebellar Ataxia Type 12 (opens NIH RePORTER)
Johns Hopkins University · 1R61NS149087-01 · NINDS · Notice Sep 19, 2026
$581KR61
- Efflux-Aware Human BBB Assembloid Assay for Brain-Penetrant Therapeutic Discovery in Medulloblastoma (opens NIH RePORTER)
Mayo Clinic Rochester · 1R61NS150150-01 · NINDS · Notice Sep 16, 2026
$501KR61
- Development of a SCN1B gene replacement therapy for DEE52 (opens NIH RePORTER)
University of Michigan at Ann Arbor · 1R61NS150122-01 · NINDS · Notice Sep 14, 2026
$378KR61
- Efficacy of Enzyme-T cells for long-term restoration of function in Mucopolysaccharidosis Type 1 (opens NIH RePORTER)
University of Minnesota · 1R61NS149137-01 · NINDS · Notice Sep 11, 2026
$487KR61
- Determining the potential of a novel non-muscle myosin II therapeutic in pediatric brain tumors (opens NIH RePORTER)
University of Florida · 1R61NS150124-01 · NINDS · Notice Sep 1, 2026
$345KR61
- Preclinical development of a prenyltransferase inhibitor to treat inflammatory neuropathy (opens NIH RePORTER)
Loyola University Chicago · 1R61NS146354-01A1 · NINDS · Notice Aug 21, 2026
$342KR61
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-225. Contact the program officer at the institute that fits your research before applying.
- NINDS · National Institute of Neurological Disorders and Stroke
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Direct costs cannot exceed 499,000 in any one year. Cumulative direct costs for the entire three-year project period may not exceed 750,000.
- Project period
- The total project period for a combined R61/R33 application submitted in response to this NOFO may not exceed three years, with no more than two years for the R61 phase and no more than two years for the R33 phase. For example, a project could have a 1-year R61 and a 2-year R33 or could have a 2-year R61 and a 1-year R33.) NIH grants policies as described in the NIH Grants Policy Statement will…
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-25-058.
- Companion NOFOs: PAR-25-059, PAR-25-060.
Other open NOFOs for R61, R33
- PAR-25-024Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)NINDS · next due Oct 20, 2026
- PAR-25-059Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)NINDS · next due Oct 20, 2026
- PAR-25-060Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)NINDS · next due Oct 20, 2026
- RFA-NS-25-023HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)NINDS · next due Jan 15, 2027
- PAR-25-053Translational Neural Devices (R61/R33 - Clinical Trial Optional)NINDS · next due Jan 28, 2027
- PAR-27-045HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)NCCIH · next due Oct 30, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.